Regenxbio Operating Margin Growth & History (RGNX)
Regenxbio's operating margin was −94.58% for fiscal 2025.
View full Regenxbio company overviewRegenxbio annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −94.58% | +185.46 pp |
| 2024 | 2024-12-31 | −280.03% | +17.09 pp |
| 2023 | 2023-12-31 | −297.12% | −63.92 pp |
| 2022 | 2022-12-31 | −233.20% | −267.22 pp |
| 2021 | 2021-12-31 | 34.01% | +111.15 pp |
| 2020 | 2020-12-31 | −77.14% | +345.75 pp |
| 2019 | 2019-12-31 | −422.89% | −463.21 pp |
| 2018 | 2018-12-31 | 40.32% | +770.47 pp |
| 2017 | 2017-12-31 | −730.15% | +693.68 pp |
| 2016 | 2016-12-31 | −1,423.84% | −1118.92 pp |
| 2015 | 2015-12-31 | −304.92% | −244.75 pp |
| 2014 | 2014-12-31 | −60.16% | +18.30 pp |
| 2013 | 2013-12-31 | −78.46% | — |
Regenxbio quarterly operating margin
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 27.09% | +323.35 pp |
| Q1 2026 | 2026-03-31 | −1,303.96% | −1317.58 pp |
| Q4 2025 | 2025-12-31 | −189.99% | +52.16 pp |
| Q3 2025 | 2025-09-30 | −176.27% | +80.28 pp |
| Q2 2025 | 2025-06-30 | −296.26% | −44.92 pp |
| Q1 2025 | 2025-03-31 | 13.62% | +422.43 pp |
| Q4 2024 | 2024-12-31 | −242.14% | +45.54 pp |
| Q3 2024 | 2024-09-30 | −256.55% | −31.89 pp |
| Q2 2024 | 2024-06-30 | −251.34% | +114.62 pp |
| Q1 2024 | 2024-03-31 | −408.80% | −63.12 pp |
| Q4 2023 | 2023-12-31 | −287.68% | −103.38 pp |
| Q3 2023 | 2023-09-30 | −224.67% | +43.31 pp |
| Q2 2023 | 2023-06-30 | −365.96% | −174.43 pp |
| Q1 2023 | 2023-03-31 | −345.68% | −23.75 pp |
| Q4 2022 | 2022-12-31 | −184.31% | −262.97 pp |
| Q3 2022 | 2022-09-30 | −267.97% | −81.61 pp |
| Q2 2022 | 2022-06-30 | −191.53% | +45.48 pp |
| Q1 2022 | 2022-03-31 | −321.93% | −88.71 pp |
| Q4 2021 | 2021-12-31 | 78.66% | +328.84 pp |
| Q3 2021 | 2021-09-30 | −186.36% | −200.46 pp |
| Q2 2021 | 2021-06-30 | −237.01% | +15.51 pp |
| Q1 2021 | 2021-03-31 | −233.22% | −19.55 pp |
| Q4 2020 | 2020-12-31 | −250.18% | +92.48 pp |
| Q3 2020 | 2020-09-30 | 14.10% | +258.29 pp |
| Q2 2020 | 2020-06-30 | −252.52% | +215.34 pp |
| Q1 2020 | 2020-03-31 | −213.67% | +3848.09 pp |
| Q4 2019 | 2019-12-31 | −342.66% | −348.67 pp |
| Q3 2019 | 2019-09-30 | −244.19% | +184.10 pp |
| Q2 2019 | 2019-06-30 | −467.86% | −483.72 pp |
| Q1 2019 | 2019-03-31 | −4,061.76% | −4138.83 pp |
| Q4 2018 | 2018-12-31 | 6.01% | +819.64 pp |
| Q3 2018 | 2018-09-30 | −428.29% | +1166.70 pp |
| Q2 2018 | 2018-06-30 | 15.86% | +245.30 pp |
| Q1 2018 | 2018-03-31 | 77.06% | +5114.87 pp |
| Q4 2017 | 2017-12-31 | −813.63% | +393.27 pp |
| Q3 2017 | 2017-09-30 | −1,594.99% | +13339.41 pp |
| Q2 2017 | 2017-06-30 | −229.44% | +400.12 pp |
| Q1 2017 | 2017-03-31 | −5,037.80% | −2174.95 pp |
| Q4 2016 | 2016-12-31 | −1,206.90% | −1083.03 pp |
| Q3 2016 | 2016-09-30 | −14,934.40% | −14289.93 pp |
| Q2 2016 | 2016-06-30 | −629.56% | −167.64 pp |
| Q1 2016 | 2016-03-31 | −2,862.85% | −2242.82 pp |
| Q4 2015 | 2015-12-31 | −123.87% | +68.57 pp |
| Q3 2015 | 2015-09-30 | −644.47% | −292.30 pp |
| Q2 2015 | 2015-06-30 | −461.92% | −423.12 pp |
| Q1 2015 | 2015-03-31 | −620.03% | −648.46 pp |
| Q4 2014 | 2014-12-31 | −192.44% | — |
| Q3 2014 | 2014-09-30 | −352.17% | — |
| Q2 2014 | 2014-06-30 | −38.80% | — |
| Q1 2014 | 2014-03-31 | 28.43% | — |
Regenxbio operating margin trends
Over the last five fiscal years, Regenxbio's operating margin decreased from −77.14% to −94.58%, a change of −17.44 percentage points. The latest reported quarter, Q2 2026, shows 27.09%.
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regenxbio source filings ↗Community posts
REGENXBIO reports three-year durability in diabetic-retinopathy study
REGENXBIO ($RGNX) presented three-year results from ALTITUDE, its Phase 2 study of sura-vec for diabetic retinopathy. Six of ten patients in the Dose 3 group who had reached the three-year visit showed an improvement of more than two steps ...